Brand name: Fluimucil Generic name: Acetylcysteine Indication: Treatment of respiratory affections characterized by thick and viscous hypersecretions:

acute bronchitis, chronic bronchitis and its exacerbations; pulmonary emphysema, mucoviscidosis and bronchiectasis. Drug Classification: Therapeutic category: Mucolytic agent Mechanism of Action: Exerts mucolytic action through its free sulfhydryl group which opens up the disulfide bonds in the mucoproteins thus lowering mucous viscosity. The exact mechanism of action in acetaminophen toxicity is unknown. It is thought to act by providing substrate for conjugation with the toxic metabolite. Dosage: Adults: 1 sachet of Acetylcysteine 200 mg or 2 sachets of Acetylcysteine 100 mg, 2-3 times a day 1 Acetylcysteine 600 mg effervescent tablet daily ( preferably in the evening) For the prevention of exacerbation, the use of FLUIMUCIL 200 mg sachets is recommended. Children: Aged up to 2 years: 1 sachet of 200 mg daily or 2 sachets of 100 mg daily. 3-7 years: 1 sachet of 200 mg twice daily or 2 sachets of 100 mg twice a day.

The duration of treatment should be 5-10 days in acute phase, whereas it may be continued in the chronic state for several months, according to the advise of physician. Special Precaution: Use with caution in patients > 60 years of age. Use with caution in patients with High blood pressure, ischemic heart disease, diabetes, increased intraocular pressure, GI or GU obstruction, asthma, thyroid disease, or prostatic hypertrophy. Not recommended for use in children. Pregnancy risk category B Adverse Effects: Hypersensitivity reactions have been reported in patients receiving acetylcysteine, including bronchospasm, angioedema, rashes and pruritus, may occur. Other adverse effects reported include nausea and vomiting, fever, syncope, sweating, arthralgia, blurred vision, disturbances of liver function. Contraindication: MAO inhibitor therapy within 14 days initiating therapy; severe hypertension; severe. Coronary artery disease, hypersensitivity to pseudoedephrine, acrivastine or any component; renal impairment. Form: Solution, as Sodium: 10%; 20% Nursing Responsibilities: Monitor effectiveness of therapy and advent of adverse/allergic effects. Instruct patient in appropriate use and adverse effects to report.